Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have received an average recommendation of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $35.38.

Several analysts recently weighed in on the company. Raymond James cut their price target on Xencor from $58.00 to $40.00 and set a “strong-buy” rating on the stock in a research note on Friday, June 14th. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price target (down previously from $36.00) on shares of Xencor in a research report on Thursday, June 13th. Royal Bank of Canada cut their price objective on shares of Xencor from $32.00 to $31.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th. BMO Capital Markets reduced their price objective on shares of Xencor from $34.00 to $32.00 and set an “outperform” rating for the company in a research note on Friday, June 14th. Finally, BTIG Research dropped their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, April 16th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in XNCR. CWM LLC lifted its holdings in Xencor by 498.7% in the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 1,147 shares during the period. Parallel Advisors LLC lifted its stake in shares of Xencor by 303.9% in the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,015 shares during the period. Signaturefd LLC boosted its holdings in shares of Xencor by 367.7% in the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,151 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Xencor by 153.7% in the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 1,316 shares during the last quarter. Finally, Allworth Financial LP grew its position in Xencor by 29,487.5% during the fourth quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 2,359 shares during the period.

Xencor Stock Up 2.2 %

Shares of Xencor stock opened at $19.80 on Friday. Xencor has a 1 year low of $16.49 and a 1 year high of $26.84. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -9.04 and a beta of 0.82. The company has a 50-day moving average of $21.74 and a 200 day moving average of $21.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.08 and a quick ratio of 7.08.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.28). Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The business had revenue of $12.80 million during the quarter, compared to analysts’ expectations of $23.07 million. During the same quarter last year, the company posted ($1.02) EPS. Xencor’s revenue for the quarter was down 32.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Xencor will post -3.5 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.